A 62-year-old man with Parkinson's disease presents with resting tremor and rigidity. His neurologist explains that the disease involves disruption of the direct and indirect pathways of the basal ganglia. Which feature best distinguishes the direct pathway from the indirect pathway in terms of their net effect on thalamic output?

Explanation

## Basal Ganglia Circuits: Direct vs. Indirect Pathway ### Functional Architecture The basal ganglia contain two major output circuits that have opposing effects on thalamic activity and motor control: | Feature | Direct Pathway | Indirect Pathway | |---------|---|---| | **Route** | Striatum → GPi/SNr → Thalamus | Striatum → GPe → STN → GPi/SNr → Thalamus | | **Neurotransmitter (Striatum)** | GABA (inhibitory) | GABA (inhibitory) | | **Effect on GPi/SNr** | Inhibition (disinhibition) | Excitation (via STN) | | **Net effect on Thalamus** | Decreased inhibition → **Increased activity** | Increased inhibition → **Decreased activity** | | **Motor outcome** | Facilitates movement | Suppresses movement | **Key Point:** The direct pathway is "go" (facilitates movement) and the indirect pathway is "no-go" (suppresses movement). In Parkinson's disease, loss of dopamine preferentially affects the indirect pathway, leading to excessive inhibition of thalamic output and hypokinesia. ### Mechanism 1. **Direct pathway disinhibition**: Striatal neurons project directly to GPi/SNr and release GABA, inhibiting these output nuclei. When GPi/SNr is inhibited, thalamic neurons are released from inhibition and fire more readily → **movement facilitation**. 2. **Indirect pathway inhibition**: Striatal neurons inhibit GPe, which normally inhibits STN. Loss of GPe inhibition allows STN to become more active. STN excites GPi/SNr, increasing their inhibitory output to thalamus → **movement suppression**. **High-Yield:** In Parkinson's disease (dopamine loss), the indirect pathway becomes overactive relative to the direct pathway, resulting in excessive thalamic inhibition and the characteristic hypokinetic features (bradykinesia, rigidity, tremor). ### Clinical Correlation **Clinical Pearl:** Levodopa and dopamine agonists preferentially activate D1 receptors on direct pathway neurons (increasing their activity) and D2 receptors on indirect pathway neurons (decreasing their activity), restoring the balance and improving motor symptoms. **Mnemonic:** **GABA-Go-No** — Direct pathway = Go (disinhibition), Indirect pathway = No-go (inhibition). Both use GABA but have opposite net effects on the thalamus.